1 Haematology and Oncology Department, Great Ormond Street Hospital For Children NHS Foundation Trust, London, UK ; 2 Molecular Haematology and Cancer Biology Unit, University College London, Institute of Child Health, London, UK.
Transl Pediatr. 2014 Jan;3(1):12-24. doi: 10.3978/j.issn.2224-4336.2014.01.09.
Wilms' tumor is the commonest renal tumor of childhood affecting one in 10,000 children. It is also one of the successes of paediatric oncology with long term survival above 90% for localised disease and 75% for metastatic disease. Successful management of Wilms' tumor necessitates meticulous attention to correct staging of the tumor and a collaborative effort between paediatric oncologists, specialist surgeons, radiologists, pathologists, and radiation oncologists. Although current treatment protocols are based on risk assignment to minimise toxicity for low risk patients and improve outcomes for those with high risk disease, challenges remain in identifying novel molecular, histological and clinical risk factors for stratification of treatment intensity. Knowledge about Wilms' tumor biology and treatment is evolving rapidly and remains a paradigm for multimodal malignancy treatment. Future efforts will focus on the use of biomarkers to improve risk stratification and the introduction of newer molecularly targeted therapies that will minimise toxicity and improve the outcomes for patients with unfavourable histology and recurrent disease. The aim of this article is to summarise advances in our understanding of the biology of Wilms' tumor and to describe the current approaches to clinical management of patients.
威尔姆斯瘤是儿童最常见的肾肿瘤,影响每 10000 名儿童中的 1 名。它也是儿科肿瘤学的成功范例之一,局部疾病的长期生存率超过 90%,转移性疾病的生存率超过 75%。成功管理威尔姆斯瘤需要对肿瘤的正确分期进行细致的关注,并需要儿科肿瘤学家、外科专家、放射科医生、病理学家和放射肿瘤学家之间的协作。尽管目前的治疗方案是基于风险分配,以最小化低危患者的毒性并提高高危疾病患者的治疗效果,但在确定新的分子、组织学和临床危险因素以分层治疗强度方面仍存在挑战。关于威尔姆斯瘤生物学和治疗的知识正在迅速发展,并且仍然是多模式恶性肿瘤治疗的范例。未来的研究重点将放在使用生物标志物来改善风险分层以及引入新的分子靶向治疗方法上,这些方法将最小化毒性并提高不良组织学和复发性疾病患者的治疗效果。本文旨在总结我们对威尔姆斯瘤生物学的理解的进展,并描述目前对患者临床管理的方法。